ATTENTION ALL CUSTOMERS:
Due to a recent change of our website, the process for submitting refill requests online has now changed.
Please click on “Sign Up Today!” to create a new account, and be sure to download our NEW Mobile app!
Thank you for your patience during this transition

Get Healthy!

  • Posted February 20, 2024

It's Tougher for Non-White Americans to Get Opioid Addiction Drug

Americans addicted to opioids who need the anti-addiction med buprenorphine are far more likely to find it if they live in a predominantly white neighborhood, new research finds.

"Access is substantially better in areas that are very white," said study lead author Coleman Drake, an assistant professor of health policy and management at Pitt Public Health in Pittsburgh.

"When you move to areas with even some racial or ethnic diversity, there is a large decline in the geographic availability of buprenorphine prescribers and prescription fills," he noted in a University of Pittsburgh news release. "In areas that are less than 95% white, for example, there's a 45 to 50% drop [in access]." 

The findings were published Feb. 20 in the Journal of Addiction Medicine.

Prior studies have looked at access to buprenorphine, but Drake's group is among the first to look at the issue at the local level.

They tracked the number of health care providers in a given ZIP code who might prescribe or dispense buprenorphine to those who needed it.

Compared to largely white urban areas, the most ethnically/racially diverse urban zip codes were between 45% to 55% less likely to have prescribers able to provide buprenorphine, Drake's group found. That gap rose to between 62% to 79% for rural parts of the United States, the study found.

Spurred by the ongoing crisis of opioid abuse and overdose deaths, efforts have been made over the past decade to ease access to buprenorphine, the team said. But any rise in access hasn't been equal for everyone.

According to Drake, more must be done to raise the number of buprenorphine prescribers in diverse communities and to promote better prescribing among those already prescribing the treatment.

More information

Find out more about buprenorphine at the Substance Abuse and Mental Health Services Administration.

SOURCE: University of Pittsburgh, news release, Feb. 20, 2024

Health News is provided as a service to Smith Drug Company site users by HealthDay. Smith Drug Company nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.
Copyright © 2024 HealthDay All Rights Reserved.

Share

Tags